title: Phosphatidylinositol 3-kinase signaling is important for smooth muscle cell replication after arterial injury.
abstract: The phosphoinositide 3-kinase [PI(3)K] pathway is a key signaling pathway important for replication of mammalian cells. In this study, we examined the role of PI(3)K in smooth muscle cell (SMC) replication after balloon catheter injury of rat carotid arteries. Protein kinase B (PKB), a downstream target of PI(3)K, was phosphorylated at 30 and 60 minutes after injury and to a lesser degree after 6 hours and 1 and 2 days but not after 7 days. Wortmannin (10 microgram per rat), a PI(3)K inhibitor, given to rats 60 and 5 minutes before and 11 hours after balloon injury, reduced the levels of phosphorylated PKB. SMC replication quantified between 24 to 48 hours was significantly reduced compared with control replication, as were the levels of cyclin D(1). Wortmannin was also administered to rats between days 7 and 8 and between days 7 and 9 after balloon catheter injury. A reduction in levels of phosphorylated PKB was detected, but no decrease in the replication of intimal SMCs was observed in either experiment. These data demonstrate that the PI(3)K signal transduction pathway plays an important role in medial but not intimal SMC replication.
authors.affiliation: Department of Pathology, University of Washington, Seattle, USA.
authors.forename: K
authors.initials: K
authors.lastname: Shigematsu
authors.forename: H
authors.initials: H
authors.lastname: Koyama
authors.forename: N E
authors.initials: NE
authors.lastname: Olson
authors.forename: A
authors.initials: A
authors.lastname: Cho
authors.forename: M A
authors.initials: MA
authors.lastname: Reidy
mesh_terms: D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D002339:Carotid Arteries / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology*; D002404:Catheterization / Q000009:adverse effects; D002455:Cell Division / Q000187:drug effects; D019938:Cyclin D1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology*; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects; D017539:Tunica Intima / Q000201:enzymology / Q000473:pathology; D000077191:Wortmannin
chemical_list: D000730:Androstadienes; D019938:Cyclin D1; D004791:Enzyme Inhibitors; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; D000077191:Wortmannin